A significant number of NSCLC patients harbor EGFR driver mutations (EGFRm NSCLC) which activate EGFR tyrosine kinase to have a ligand-independent activity, resulting in tumorigenesis (1–3). Here, EGFR is linked to non-small cell lung carcinoma.